Grants and Contributions:

Back to search

Title:

E!7296 COVANEXT: Unlocking druggability of disordered proteins

Agreement Number:

1028974

Agreement Value:

$500,000.00

Agreement Date:

Apr 1, 2025 - Mar 30, 2027

Description:

E!7296 COVANEXT: Unlocking druggability of disordered proteins Co-International partner: Nuage Therapeutics SL, Spain To advance the development of NT-A, a first-in-class covalent therapeutic for small cell lung cancer (SCLC).

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Mississauga, Ontario, CA L5N 8G4

Reference Number:

172-2025-2026-Q1-1028974

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

716905096

Recipient Type:

For-profit organization

Recipient's Operating Name:

Dalriada

Recipient's Legal Name:

Dalriada Drug Discovery Inc.

Federal Riding Name:

Mississauga--Streetsville

Federal Riding Number:

35063

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

541710